middle.news
How Syntara’s SNT-5505 Is Transforming Myelofibrosis Treatment Outcomes
8:45am on Friday 13th of June, 2025 AEST
•
Healthcare
Read Story
How Syntara’s SNT-5505 Is Transforming Myelofibrosis Treatment Outcomes
8:45am on Friday 13th of June, 2025 AEST
Key Points
73% of evaluable patients achieved significant symptom improvement at 24 weeks
44% of patients showed meaningful spleen volume reduction without increasing ruxolitinib dose
SNT-5505 demonstrated a strong safety profile with no treatment-related serious adverse events
Final Phase 2 results expected in Q3 2025 after all patients complete 52 weeks
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SYNTARA (ASX:SNT)
OPEN ARTICLE